No vaccine yet but AstraZeneca has agreement for 400 million dosesChristian Fernsby ▼ | May 21, 2020
AstraZeneca has concluded the first agreements for at least 400 million doses and has secured total manufacturing capacity for one billion doses so far and will begin first deliveries in September 2020.
AstraZeneca received support of more than $1bn from the U.S. Biomedical Advanced Research and Development Authority (BARDA) for the development, production and delivery of the vaccine, starting in the fall.
The development programme includes a Phase III clinical trial with 30,000 participants and a paediatric trial.
In addition, the Company is engaging with international organisations such as the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance and the World Health Organisation (WHO), for the fair allocation and distribution of the vaccine around the world.
AstraZeneca is also in discussions with governments around the world to increase access.
Furthermore, AstraZeneca is in discussions with the Serum Institute of India and other potential partners to increase production and distribution.
AstraZeneca recently joined forces with the UK Government to support Oxford University’s vaccine and has progressed rapidly in its efforts to expand access around the world. ■